Komori
Rohto Pharmaceutical (4527) · InitiativeAdvanced

Maximising Human Capital, Talent Development and Diversity

First written in FY2023. 2 of 3 entries say "Advanced", first in FY2024. Latest entry: FY2026.

3entries
4years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2023AdvancedFY2024 – FY20262023: 120232024: 120242025: 020252026: 12026
Same theme, other companies
Multifaceted Improvement Targets for Human Capital MetricsA theme 61 companies write about · 0 as a headwind · 61 as a tailwind

The whole theme swung hardest in 2026: 11 of 59 companies on the "Worse" side.

18 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 61 companies compared. The sentences above are computed from all 61.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「Rate of male employees taking parental leave 91.4% 100% Overtime work (hours/month) 11.7 0 Well-being survey score Average for 5 items 6.99 pt Full marks for all items」

    The Company updated its human capital KPIs and disclosed results and fiscal 2030 targets, including a 91.4% rate of male employees taking parental leave, an 80.6% paid leave utilisation rate and a 31.0% proportion of women in management positions.
  2. FY2024AdvancedAnnual report

    「Rate of male employees taking parental leave 46.4% 100% Paid leave utilisation rate 80.0% At least 80% Number of occupational accidents resulting in leave 3 0」

    Regarding maximising human capital, the Company disclosed fiscal 2023 results and fiscal 2030 targets for the rate of male employees taking parental leave, paid leave utilisation, occupational accidents, employee engagement and health management.
  3. FY2023First statedAnnual report

    「Based on the view that talent development will become increasingly important to place these initiatives on a growth trajectory, the Company revised its personnel and compensation systems in October 2022. The compensation structure reflects the value of work and the degree of contribution to performance. By enabling each employee to grow as a "professional," the Company will pursue the creation of "value in work" and the realisation of well-being.」

    With maximising human capital as a material issue, the Company has established initiatives to revise its personnel and compensation systems, promote diversity management and develop talent. It has set multiple KPIs and targets, including increasing the rate of male employees taking parental leave from 26.5% to 100% by fiscal 2030 and the paid leave utilisation rate from 72.9% to at least 80%.
Moved together

"Establishing a market position through high-value-added products and new brands" moved the same way as this thread, in the same document, in 2 of its 3 moves.

222222★123456
  1. ★This thread
  2. 1Establishing a market position through high-value-added products and new brands2×
  3. 2Technological Innovation and Strengthening the R&D Platform2×
  4. 3Globalization Centered on Asia and Expansion into Emerging Markets2×
  5. 4Initiatives to make food and regenerative medicine future pillars of the business2×
  6. 5Active investment in new fields and research and development2×
  7. 623 consecutive periods of revenue growth and record-high profits2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Rohto Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.